Market Overview

XenoPort May Be Beneficiary of Biogen Patent Filings

Share:
Related BIIB
5 NASDAQ Healthcare Stocks With The Highest EPS
3 Biotech Stocks See Growing Short Interest
Stock Market News for May 21, 2015 - Market News (Zacks)
Related XNPT
Catalysts To Watch For In RBC Capital's 2015 Top Small-Cap Biotechs
Jefferies Weighs In On Specialty Pharmaceuticals After Management Meetings, Raises Price Targets On 5 Stocks

Brian Abrahams, a Wells Fargo analyst, believes that Biogen (NASDAQ: BIIB) MS pill patents will be a positive boost for XenoPort (NASDAQ: XNPT).

Further patent applications could provide patent protection until 2032 for Biogen's BG-12, which should benefit XenoPort's '829 drug, an earlier stage derivative of BG-12, with added protection from generic competition.

BIIB is currently up 1.5 percent in pre-market trading, while XNPT is currently unchanged.

Latest Ratings for BIIB

DateFirmActionFromTo
Apr 2015CitigroupMaintainsBuy
Apr 2015OppenheimerAssumesPerform
Apr 2015NomuraMaintainsNeutral

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Analyst Ratings

 

Related Articles (BIIB + XNPT)

Around the Web, We're Loving...